LYKA LABS
|
LYKA LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -2.81 | 2.24 | -0.75 | -4.30 | 13.59 |
| CEPS(Rs) | -0.55 | 4.12 | 3.08 | 0.32 | 19.45 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 25.76 | 29.22 | 17.86 | 9.12 | 4.65 |
| Tax Rate(%) | 11.41 | 28.69 | -180.60 | 0.14 | 35.11 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -2.71 | 12.95 | 14.12 | 18.09 | 52.12 |
| EBIT Margin(%) | -6.58 | 9.67 | 3.56 | -1.40 | 40.90 |
| Pre Tax Margin(%) | -9.17 | 8.03 | -0.84 | -14.15 | 30.53 |
| PAT Margin (%) | -8.12 | 5.73 | -2.36 | -14.13 | 19.81 |
| Cash Profit Margin (%) | -1.54 | 10.62 | 9.16 | 1.07 | 28.75 |
| Performance Ratios | |||||
| ROA(%) | -5.95 | 4.76 | -1.70 | -7.80 | 21.40 |
| ROE(%) | -10.64 | 9.71 | -6.02 | -63.63 | - |
| ROCE(%) | -5.96 | 10.01 | 3.26 | -1.00 | 56.68 |
| Asset Turnover(x) | 0.73 | 0.83 | 0.72 | 0.55 | 1.08 |
| Sales/Fixed Asset(x) | 0.65 | 0.79 | 0.70 | 0.56 | 1.02 |
| Working Capital/Sales(x) | 13.70 | 6.66 | 8.63 | 8.02 | -4.12 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.53 | 1.26 | 1.42 | 1.80 | 0.98 |
| Receivable days | 110.99 | 92.33 | 77.33 | 75.65 | 25.51 |
| Inventory Days | 37.08 | 29.04 | 27.12 | 29.71 | 11.76 |
| Payable days | 115.42 | 88.82 | 87.52 | 104.00 | 92.01 |
| Valuation Parameters | |||||
| PER(x) | - | 44.97 | - | - | 9.98 |
| PCE(x) | -80.82 | 24.51 | 34.43 | 322.97 | 6.97 |
| Price/Book(x) | 1.74 | 3.46 | 5.93 | 11.47 | 29.17 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.61 | 2.87 | 3.61 | 4.10 | 2.59 |
| EV/Core EBITDA(x) | - | 19.68 | 23.38 | 18.86 | 4.86 |
| EV/EBIT(x) | -24.47 | 29.63 | 101.43 | -293.50 | 6.33 |
| EV/CE(x) | 1.47 | 2.78 | 3.21 | 3.25 | 2.71 |
| M Cap / Sales | 1.24 | 2.60 | 3.15 | 3.45 | 2.00 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -7.26 | 24.55 | 19.47 | -52.05 | 125.02 |
| Core EBITDA Growth(%) | -99.94 | 17.46 | -15.17 | -80.40 | 385.97 |
| EBIT Growth(%) | -163.05 | 238.57 | 404.20 | -101.64 | 573.04 |
| PAT Growth(%) | -231.54 | 402.74 | 80.08 | -134.21 | 480.98 |
| EPS Growth(%) | -225.21 | 398.40 | 82.52 | -131.67 | 437.53 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.53 | 0.36 | 0.96 | 2.58 | 9.76 |
| Current Ratio(x) | 1.17 | 1.45 | 1.34 | 1.36 | 0.53 |
| Quick Ratio(x) | 0.92 | 1.18 | 1.09 | 1.21 | 0.44 |
| Interest Cover(x) | -2.54 | 5.90 | 0.81 | -0.11 | 3.94 |
| Total Debt/Mcap(x) | 0.30 | 0.11 | 0.16 | 0.22 | 0.33 |
Compare Financial Ratios of peers of LYKA LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LYKA LABS | ₹229.0 Cr | 2.1% | -12.2% | -45.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,870.0 Cr | -1.4% | 2.4% | 17.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,946.0 Cr | 12.2% | 23.1% | 21.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,907.0 Cr | 2.4% | 5.3% | 41.7% | Stock Analytics | |
| CIPLA | ₹118,674.0 Cr | 1.7% | 0.7% | -3.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,648.7 Cr | 3% | -14.9% | -10.2% | Stock Analytics | |
LYKA LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LYKA LABS | 2.1% |
-12.2% |
-45.9% |
| SENSEX | 2.4% |
1.5% |
-4.3% |
You may also like the below Video Courses
